Trials / Completed
CompletedNCT01095393
National Data Bank for Rheumatic Disease Registry Study of Safety in Patients With Rheumatoid Arthritis Treated With Cimzia® or Disease-modifying Antirheumatic Drugs (DMARDs)
National Data Bank for Rheumatic Disease (NDB) Registry Study of Safety in Rheumatoid Arthritis (RA) Patients Treated With Certolizumab Pegol (CZP; Cimzia®) and Non-biologic Disease-modifying Antirheumatic Drug (DMARD) Therapies
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 12,500 (actual)
- Sponsor
- UCB Pharma · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
Observational registry to assess the longer-term risk of serious infections and malignancies reported with TNFα-blocker therapy, as well as the longer-term risk of cardiovascular and thromboembolic events in adult Rheumatoid Arthritis (RA) patients treated with Cimzia® as compared to non-biologic DMARD-treated controls.
Conditions
Timeline
- Start date
- 2009-09-01
- Primary completion
- 2016-12-13
- Completion
- 2019-12-31
- First posted
- 2010-03-30
- Last updated
- 2020-07-16
Source: ClinicalTrials.gov record NCT01095393. Inclusion in this directory is not an endorsement.